1)Glaxo's ViiV touts more two-drug HIV success with monthly injectable win 2)Monthly HIV injection could free patients from gruelling drug regimen
ViiV and Janssen progress two drug injectable HIV-1 treatmentHIV (Human Immunodeficiency Virus)Janssen Sciencies Ireland UCViiV Healthcare
参考资料: Glaxo's ViiV touts more two-drug HIV success with monthly injectable win Monthly HIV injection could free patients from gruelling drug regimen
once-monthly injectable regimen has similar efficacy, safety and tolerability to a daily, oral three-drug regimen for the treatment of HIV,” stated John C. Pottage, Jr., ViiV’s chiefscientificand medical officer. “We are also encouraged by patient preference...
116. Antiviral Activity and Safety of Long-acting Cabotegravir (CAB LA) Plus Long-acting Rilpivirine (RPV LA), Administered Every 2 Months (Q2M), in Hiv-po... BACKGROUND. Long-acting (LA) cabotegravir (CAB) and rilpivirine (RPV) injectable suspensions have demonstrated efficacy in phase ...
Scanning electron micrograph of HIV-1 (in green) budding from cultured lymphocyte. Credit: C Goldsmith / Wikipedia. ViiV Healthcare has begun a rolling submission of a new drug application (NDA) with the US Food and Drug Administration (FDA) for its long-acting cabotegravir to prevent human...
(Pfizer) and Shionogi Limited (Shionogi) as shareholders, today announced that the US Food and Drug Administration (FDA) approved Apretude, the first and only long-acting injectable pre-exposure prophylaxis ...
China clears ViiV, J&J injectable HIV treatment News ViiVViiV Healthcare and Johnson & Johnson have been granted approval in China for a long-acting HIV therapy that frees patients from the need to take daily pills to keep the virus at bay. China’s National Medical Products Administration (...
ViiV Healthcare has submitted its once-monthly two-drug injected treatment for HIV to the US Food and Drug Administration (FDA).
Preliminary testing of two long-acting injectable drugs indicates it might be possible to keep HIV at bay indefinitely with injections every month or two. Johnson & Johnson and partner ViiV Healthcare, which specializes in HIV drugs, announced results from the first 32 weeks of the planned 96-...